For the quarter ended June 30, 2011, the Company's marketing and selling expenses decreased 38%, or $33,000, to $53,000, compared to $86,000 for the same period in 2010. This decrease was primarily due to a reduction in sales commissions and royalties due to lower royalty revenues.
The Company recorded a gain of $103,000 on research and development activity compared to an expense of $256,000 for the same period in 2010. The gain was a result of receiving proceeds during the quarter on sale of certain laboratory equipment of $120,000, combined with lower research and development expenses following the elimination of its laboratory activities.
General and administrative expenses increased 2%, or $13,000, to $585,000 for the three months ended June 30, 2011, compared to approximately $572,000 for the same period in 2010. The increase was primarily due to recognition of $61,000 in accelerated depreciation expense related to leasehold improvements as a result of a reduction in the term of our headquarters lease. This increase was offset by a decrease in office expense.
Other income decreased 106%, or $222,000, to an expense of $12,000 for the three months ended June 30, 2011, compared to income of $210,000 for the comparable period in 2010. This decrease is due to a change in unrealized gain (loss) on the fair value of a warrant to purchase common stock.
Net loss increased 12%, or $58,000, to $539,000 for the three months ended June 30, 2011, compared to $481,000 for the same period in 2010. The increase in net loss reflects lower revenues and the change in the unrealized gain (loss) on fair value of warrant to purchase common stock.
Comparison of the Year to Date Six Months Ended June 30, 2011 and 2010 Total revenues, which consist of licensing fees, research and development revenues, and royalty revenue from SCOLR's collaboration agreements, decreased 51%, or $197,000, to $192,000 for the si
|SOURCE SCOLR Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved